September 7, 2010
Genta Incorporated to Present at the Rodman & Renshaw Annual Global Investment Conference
August 12, 2010
Genta Incorporated Reports Second Quarter 2010 Corporate Highlights and Financial Results
August 5, 2010
Genta Incorporated to Host Conference Call to Discuss Second Quarter 2010 Highlights and Financial Results
July 30, 2010
Board of Directors of Genta Incorporated Announce Reverse Split of Company’s Common Stock
June 11, 2010
Genta Incorporated Announces Webcast of 2010 Annual Shareholders Meeting
June 7, 2010
Tesetaxel Results from Two Clinical Dose-Ranging Trials Presented at ASCO
June 6, 2010
Pooled Results of Early Endpoints from Phase 3 Trials of Genasense® in Advanced Melanoma Presented at ASCO
May 13, 2010
Genta Incorporated Announces First Quarter 2010 Financial Results
May 6, 2010
Genta Incorporated to Host Conference Call to Discuss First Quarter 2010 Highlights and Financial Results
May 4, 2010
Genta Announces Clinical Presentations on Lead Compounds, Tesetaxel and Genasense®, at 2010 Annual ASCO Meeting
April 28, 2010
Genta Incorporated to Present at the 2010 BIO International Convention
April 20, 2010
Genta Presents Initial Clinical Data on Use of Gallium Compounds as Treatment for Serious Infections
April 6, 2010
Genta’s Tesetaxel Granted Fast Track Designation by FDA for Advanced Gastric Cancer
March 31, 2010
Genta Initiates Confirmatory Phase 2b Trial of Tesetaxel in Gastric Cancer
March 29, 2010
Genta Incorporated Reports Fourth Quarter and 2009 Year-End Financial Results
March 24, 2010
Genta Incorporated to Host Conference Call to Discuss Fourth Quarter 2009 Highlights and Financial Results
March 8, 2010
Genta Announces $25 Million Financing
February 25, 2010
Genta Initiates Once-Weekly Treatment Schedule for Tesetaxel, a Novel Oral Tubulin Inhibitor, in New Dose-Ranging Study
February 10, 2010
Genta Receives $2.8 Million in Non-Dilutive Proceeds from Tax Sale and Designation by EMEA as a Small Business Entity
February 8, 2010
Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Melanoma
February 2, 2010
Genta Incorporated to Present at the 12th Annual BIO CEO & Investor Conference
January 27, 2010
MEDCI Announces Strategic Alliance with Genta Incorporated to Secure Tesetaxel Licensing Partner
January 12, 2010
Two New Studies Show Gallium-Containing Compounds Significantly Increase Bone Strength in Standard Models of Osteoporosis
